Wh 380 F Form: Fill & Download for Free

First of all, it depends on what you mean by STD - do you mean FMLA leave, as defined by federal law? Or your company’s STD leave policy? Or your state’s STD leave or payment program! Or your STD insurance payments? I don’t know how can this be answered without clarity on what you’re asking. What qualifies is going to depend on what you’re asking. And, for anything other than FMLA, it is going to depend on your state, your company and /or your specific insurance plan. So no one can answer that other than the state, company, or insurance provider.As for FMLA leave,FMLA eligibility requires the following criteria:The employee must have been employed with the company for 12 monthsThe employee must have worked at least 1,250 hours during the 12 months prior to the start of FMLA leaveThe employer is one who employs 50 or more employees within a 75-mile radius of the worksiteThe purpose of FMLA is to provide a means for families to balance both work and medical or personal needs without sacrificing their job security. An employee may request FMLA for any of the following:To prepare for the birth of a son or daughterTo care for a newborn childFor adoption or foster care placement of a son or daughterTo care for a spouse, son, daughter, or parent with a serious health conditionTo take care of the employees own serious health conditionTo transition employees or spouses who are called to active dutyAs defined under FMLA, a "serious health condition" means any illness, injury, impairment, or physical or mental condition that involves either inpatient care or continuing treatment by a health care provider. Additionally, for determining what qualifies for FMLA-related leave, the regulations only include an employee's spouse, child, or parent as family members. Because reasons for taking time off from work under the FMLA vary, it is important to check whether your reason for leave request fits within the type of allowable events within your employer's policies -- or risk getting denied. Under some circumstances, employees may take FMLA leave on an intermittent or reduced schedule basis. That means an employee may take leave in separate blocks of time or by reducing the time he or she works each day or week for a single qualifying reason. When leave is needed for planned medical treatment, the employee must make a reasonable effort to schedule treatment so as not to unduly disrupt the employer's operations. If the employee and the reaskn for leave qualify, a certification from a foreign provider is sufficient under FMLA, so long as that person is authorized to practice in his or her country, which is understandably a difficult thing to verify. The Department of Labor is more flexible, stating “If the employee or the employee’s family member is visiting another country, or a family member resides in another country, and a serious health condition develops, the employer must accept a medical certification, as well as second and third opinions, from a health care provider who practices in that country.” However, you can still require sufficient information, such as that contained in the WH 380-F, which is the Department of Labor’s model certification form for care of family members. The key details contained in this form must be filled in and understandable, sufficient to make a determination whether the FMLA applies. If the note is written in another language, it is not invalid, but you can require the employee to have it translated.

How do you calculate flow rate in a pipe?If the liquid is flowing through a pipe, the area is A = πr2, where r is the radius of the pipe. For a rectangle, the area is A = wh where w is the width, and h is the height. The flow rate can be measured in meters cubed per second (m3/s), or in liters per second (L/s).We regularly get asked about the water flow capacity of different pipe sizes, and which is the best roof drain for a specific pipe size. Unfortunately, recommendations aren't that straightforward because you also need to account for water pressure, material friction and more.That said, we put together the following tables to serve as general guides for estimating a pipe's water flow capacity. If you have questions, please call our Drain Wizard at 800-635-0384.Water Flow (GPM/GPH) based on Pipe Size and Inside/Outside DiametersAssume Gravity to Low Pressure. About 6 f/s flow velocity, also suction side of pumpAssume Average Pressure (20-100PSI). About 12 f/s flow velocityAssume "High Pressure" PEAK flow. About 18 f/s flow velocityPipe Size (Sch. 40)I.D. (range)O.D.GPM(w/ min. PSI loss & noise)GPH(w/ min. PSI loss & noise)GPM(w/ min. PSI loss & noise)GPH(w/ min. PSI loss & noise)GPM(w/ min. PSI loss & noise)GPH(w/ min. PSI loss & noise)1/2"0.5 - 0.6"0.85"742014840211,2603/4"0.75 - 0.85"1.06"11660231,410362,1601"1 - 1.03"1.33"16960372,200583,4801-1/4"1.25 - 1.36"1.67"251,500623,7501006,0001-1/2"1.5 - 1.6"1.9"352,100814,8301267,5602"1.95 - 2.05"2.38"553,3001277,65020012,0002-1/2"2.35 - 2.45"2.89"804,80019011,40030018,0003"2.9 - 3.05"3.5"1408,40027316,35042525,5004"3.85 - 3.95"4.5"24014,40048028,80070042,0005"4.95" - 5.05"5.563"38022,80075045,0001,10066,0006"5.85 - 5.95"6.61"55033,000110066,0001700102,0008"7.96"8.625"95057,0001900114,0002800168,000Water Flow (GPM) Capacity Based on ID Size and PressurePRESSUREFLOW IN GPM THROUGH PIPE ID IN INCHESPSI1"1.25"1.5"2"2.5"3"4"20264776161290468997303258942003605821240403868110234421680144950437712426447576716356047851372915248461804755395153329591955203510062112180384690111523771257012620343377912582681150771392244788591388295820090162262558100416213455Water Flow Capacity in Steel Pipes (sch 40)Pipe SizeMaximum Flow (gal/min)Velocity (ft/s)Head Loss (ft/100 ft)2"454.33.92-1/2"755.04.13"1305.63.94"2606.64.06"8008.94.08"1,60010.33.810"3,00012.24.012"4,70013.44.014"6,00014.24.016"8,00014.53.518"10,00014.33.020"12,00013.82.424"18,00014.42.1

REFERENCES TO Some of Dr YOUNGS WORK ADDED BELOWOutrage? Fear mongering? Get a grip, 45 years of research by Dr Henry You g out of mercer medical and more than 60 published peer reviewed papers by Dr Young in medical journals conclusively prove that nicotine delivery via cigarettes, cigars, pipes, and yes vapes including the chemicals used in non nicotine vape pods and fluids for vaping KILL EVERY TOTIPOTENT AND PLEUROPOTENT STEM CELL IN THE BLOOD! Your body sheds billions of dead cells a day these new stem cells in the blood replace and nicotine and the chemicals in vapes and/or nicotine obliterates them, destroys them, so the dead cells are not replaced as they should be and that’s fear mongering? The slow painful death you guarantee yourself with each puff is fear mongering? Lol. Okay, whatever you say. How about outrage over the misinformation spread by addicts to support and justify their own addiction while simultaneously taking down the lives of others who read and believe their rhetoric?EDIT: you’ll see below Mike McFadden and other pro nicotine fanatics touting vaping as a safe alternative to smoking. It’s BS. Both the chemicals in non nicotine vape products and nicotine obliterate stem cells. The basis of this genius argument appears to be no links to the 45 years of research on the subject of nicotine that are easily found via google search. As we all know Quora doesn’t allow links to sites that redirect readers from Quora. Additionally, he purports that vaping hasn’t been around long enough to be the subject of Dr. Young’s research completely oblivious to the fact the chemicals and nicotine used in vape products in fact has been the very subject of said research. McFadden would have you believe that because the deadly chemicals are delivered via vaping they are safe. That’s like saying arsenic will kill you if swallowed but not if vaped. It’s absurd. No one, not I or anyone that opposes touting vaping as a “safe alternative” to smoking EVER made the preposterous claim that nicotine from cigarettes is safer than nicotine from vaping. NICOTINE FROM ANY DELIVERY MECHANISM OBLITERATES STEM CELLS IN THE BLOOD PERIOD. McFadden ends his absurdity by implying my position on vaping is somehow supporting big Pharma or the tobacco industry, no, what credible medical research has conclusively proven is they’re all equally worthless and deadly. Its all a bunch of nonsense and he (McFadden) and his ilk are misleading kids into a slow painful but certain miserable death.1. Young HE. Epidermal ridge formation during limb regeneration in the adult salamander, Ambystoma annulatum. Proceedings of the Arkansas Academy of Science, 31:107-109, 1977.2. Young HE. Anomalies during limb regeneration in the adult salamander, Ambystoma annulatum. Proceedings of the Arkansas Academy of Science, 31:110- 111, 1977.3. Young HE. Limb Regeneration in the Adult Salamander, Ambystoma annulatum Cope 1889 (Amphibia: Ambystomatidae). University of Arkansas Library Press, copyright -1977.4. Young HE, Bailey CF, Dalley BK. Environmental conditions prerequisite for complete limb regeneration in the postmetamorphic adult land-phase salamander, Ambystoma. Anatomical Record, 206:289-294, 1983.5. Young HE, Bailey CF, Dalley BK. Gross morphological analysis of limb regeneration in postmetamorphic adult Ambystoma. Anatomical Record, 206:295-306, 1983.6. Young HE. A Temporal Examination of Glycoconjugates During the Initiation Phase of Limb Regeneration in Adult Ambystoma. Texas Tech University Library Press, copyright - 1983.7. Young HE, Dalley BK, Markwald RR. Identification of hyaluronate within peripheral nervous tissue matrices during limb regeneration. Edited by Coates, P.W., Markwald, R.R., Kenny, A.D., Alan R. Liss, Inc., New York. In: Developing and Regenerating Vertebrate Nervous Systems, Neurology and Neurobiology, 6:175-183, 1983.8. Young HE, Bailey CF, Markwald RR, Dalley BK. Histological analysis of limb regeneration in postmetamorphic adult Ambystoma. Anatomical Record, 212:183-194, 1985.9. Young HE, Carrino DA, Caplan AI. Initial characterization of small proteoglycanssynthesized by embryonic chick leg muscle-associated connective tissues. Connective Tissue Research, 17:99-118, 1988.10. Young HE, Dalley BK, Markwald RR. Effect of selected denervations on glycoconjugate composition and tissue morphology during the initiation phase of limb regeneration in adult Ambystoma. Anatomical Record, 223:223-230, 1989.11. Young HE, Dalley BK, Markwald RR. Glycoconjugates in normal wound tissue matrices during the initiation phase of limb regeneration in adult Ambystoma. Anatomical Record, 223:231-241, 1989.12. Young HE, Young VE, Caplan AI. Comparison of fixatives for maximal retention of glycoconjugates for autoradiography, including use of sodium sulfate to release unincorporated radiolabeled [35S]sulfate. Journal of Histochemistry and Cytochemistry, 37:223-228, 1989.13. Young HE, Carrino DA, Caplan AI. Histochemical analysis of newly synthesized and resident sulfated glycosaminoglycans during musculogenesis in the embryonic chick leg. Journal of Morphology, 201:85-103, 1989.14. Young HE, Carrino DA, Caplan AI. Changes in synthesis of sulfated glycoconjugates during muscle development, maturation, and aging in embryonic to senescent CBF-1 mouse. Mechanisms of Ageing and Development, 53:179-193, 1990.15. Young HE, Morrison DC, Martin JD, Lucas PA. Cryopreservation of embryonic chick myogenic lineage-committed stem cells. Journal of Tissue Culture Methods, 13:275-284, 1991.16. Shoptaw JH, Bowerman S, Young HE, Lucas PA. Use of gelfoam as a substrate for osteogenic cells of marrow. Surgical Forum XLII:537-538, 1991.17. Bowerman SG, Taylor SS, Putnam L, Young HE, Lucas PA. Transforming growth factor-b (TGF-b) stimulates chondrogenesis in cultured embryonic mesenchymal cells. Surgical Forum XLII:535-536, 1991.18. Young HE, Sippel J, Putnam LS, Lucas PA, Morrison DC. Enzyme-linked immuno-culture assay. Journal of Tissue Culture Methods, 14:31-36, 1992.19. Young HE, Ceballos EM, Smith JC, Lucas PA, Morrison DC. Isolation of embryonic chick myosatellite and pluripotent stem cells. Journal of Tissue Culture Methods, 14:85-92, 1992.20. Young HE, Ceballos EM, Smith JC, Mancini ML, Wright RP, Ragan BL, Bushell I, Lucas PA. Pluripotent mesenchymal stem cells reside within avian connective tissue matrices. In Vitro Cellular & Developmental Biology, 29A:723-736, 1993.21. Pate DW, Southerland SS, Grande DA, Young HE, Lucas PA. Isolation and differentiation of mesenchymal stem cells from rabbit muscle. Surgical Forum, XLIV:587-589,1993.22. Rogers JJ, Adkison LR, Black AC Jr, Lucas PA, Young HE. Differentiation factors induce expression of muscle, fat, cartilage, and bone in a clone of mouse pluripotent mesenchymal stem cells. The American Surgeon 61(3):231-236, 1995.23. Young HE, Mancini ML, Wright RP, Smith JC, Black AC Jr, Reagan CR, Lucas PA. Mesenchymal stem cells reside within the connective tissues of many organs. Developmental Dynamics 202:137-144, 1995.24. Black AC Jr, Goolsby LW, Cohen GA, Young HE. Effects of prenatal ethanol exposure on the hippocampal neurochemistry of albino rats at 90 days of postnatal age. Am. J. Obstet. Gynecol. 173:514-519, 1995.25. Lucas PA, Calcutt AF, Southerland SS, Wilson JA, Harvey RL, Warejcka D, Young HE. A population of cells resident within embryonic and newborn rat skeletal muscle is capable of differentiating into multiple mesodermal phenotypes. Wound Repair and Regeneration 3:449-460, 1995.26. Warejcka DJ, Harvey R, Taylor BJ, Young HE, Lucas PA. A population of cells isolated from rat heart capable of differentiating into several mesodermal phenotypes. J. Surg. Res. 62:233-242, 1996.27. Lucas PA, Warejcka DJ, Zhang L-M, Newman WH, Young HE. Effect of rat mesenchymal stem cells on the development of abdominal adhesions after surgery. J. Surg. Res. 62:229-232, 1996.28. Lucas PA, Warejcka DJ, Young HE, Lee BY. Formation of abdominal adhesions is inhibited by antibodies to transforming growth factor-beta1. J. Surg. Res. 65:135-138, 1996.29. Dixon K, Murphy RW, Southerland SS, Young HE, Dalton ML, Lucas PA. Recombinant human bone morphogenetic proteins-2 and 4 (rhBMP-2 and rhBMP-4) induce several mesenchymal phenotypes in culture. Wound Repair and Regeneration 4:374-380, 1996.30. Young HE, Wright RP, Mancini ML, Lucas PA, Reagan CR, Black AC Jr. Bioactive factors affect proliferation and phenotypic expression in pluripotent and progenitor mesenchymal stem cells. Wound Repair and Regeneration 6(1):65-75, 1998.31. Young HE, Rogers JJ, Adkison LR, Lucas PA, Black AC Jr. Muscle morphogenetic protein induces myogenic gene expression in Swiss-3T3 cells. Wound Rep Reg 6(6):543-554, 1998.32. Young HE, Steele T, Bray RA, Detmer K, Blake LW, Lucas PA, Black AC Jr. Human progenitor and pluripotent cells display cell surface cluster differentiation markers CD10, CD13, CD56, CD90 and MHC Class-I. Proc. Soc. Exp. Biol. Med. 221:63-71, 1999.33. Young HE. Pluripotent stem cells. Edited by M.A. Brown and S. Neufield, Cambridge Healthtech Institute Press, Newton Upper Falls, MA. In: Second Annual Symposium on Tissue Engineering / Regenerative Healing / Stem Cell Biology, 469-530, 1999.34. Young HE. Stem cells and tissue engineering. In: Gene Therapy in Orthopaedic and Sports Medicine, J. Huard and F.H. Fu, eds., Springer-Verlag New York, Inc., Chap. 9, pg. 143-173, 2000.35. Young HE, Duplaa C, Young TM, Floyd JA, Reeves ML, Davis KH, Mancini GJ, Eaton ME, Hill JD, Thomas K, Austin T, Edwards C, Cuzzourt J, Parikh A, Groom J, Hudson J, Black AC Jr. Clonogenic analysis reveals reserve stem cells in postnatal mammals. I. Pluripotent mesenchymal stem cells. Anat. Rec. 263:350-360, 2001.36. Young HE, Steele T, Bray RA, Hudson J, Floyd JA, Hawkins K, Thomas K, Austin T, Edwards C, Cuzzourt J, Duenzl M, Lucas PA, Black AC Jr. Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat. Rec. 264:51-62, 2001.37. Romero-Ramos M, Vourc’h P, Young HE, Lucas PA, Wu Y, Chivatakarn O, Zaman R, Dunkelman N, El-Kalay MA, Chesselet M-F. Neuronal differentiation of stem cells isolated from adult muscle. J Neurosci Res 69:894-907, 2002.38. Young HE. Existence of reserve quiescent stem cells in adults, from amphibians to humans. Curr Top Microbiol Immunol. 280:71-109, 2004.39. Young HE, Black Jr AC. Adult stem cells. Anat. Rec. 276A:75-102, 2004.40. Young HE, Duplaa C, Romero-Ramos M, Chesselet M-F, Vourc’h P, Yost MJ, Ericson K, Terracio L, Asahara T, Masuda H, Tamura-Ninomiya S, Detmer K, Bray RA, Steele TA, Hixson D, El-Kalay M, Tobin BW, Russ RD, Horst MN, Floyd JA, Henson NL, Hawkins KC, Groom J, Parikh A, Blake L, Bland LJ, Thompson AJ, Kirincich A, Moreau C, Hudson J, Bowyer III FP, Lin TJ, Black Jr AC. Adult reserve stem cells and their potential for tissue engineering. Cell Biochem Biophys, 40(1):1-80, 2004.41. Young HE, Duplaa C, Yost MJ, Henson NL, Floyd JA, Detmer K, Thompson AJ, Powell SW, Gamblin TC, Kizziah K, Holland BH, Boev A, Van de Water JM, Godbee DC, S. Jackson, M. Rimando, Edwards CR, Wu E, Cawley C, Edwards PD, Macgregor A, Bozof R, Thompson TM, Petro Jr GJ, Shelton HM, McCampbell BL, Mills JC, Flynt FL, Steele TA, Kearney M, Kirincich-Greathead A, Hardy W, Young PR, Amin AV, Williams RS, Horton MM, McGuinn S, Hawkins KC, Ericson K, Terracio L, Moreau C, Hixson D, Tobin BW, Hudson J, Bowyer III FP, Black Jr AC. Clonogenic analysis reveals reserve stem cells in postnatal mammals. II. Pluripotent epiblastic-like stem cells. Anat. Rec. 277A:178-203, 2004.42. Vourc'h P, Romero-Ramos M, Chivatakarn O, Young HE, Lucas PA, El-Kalay M, Chesselet M-F. Isolation and characterization of cells with neurogenic potential from adult skeletal muscle. Biochemical and Biophysical Research Communications 317:893-901, 2004.43. Seruya M, Shah A, Pedrotty D, du Laney T, Melgiri R, McKee JA, Young HE, Niklason LE. Clonal Population of adult stem cells: life span and differentiation potential. Cell Transplant 13:93-101, 200444. Young HE, Black AC Jr. Differentiation potential of adult stem cells. In: Contemporary Endocrinology: Stem Cells in Endocrinology, L.B. Lester, ed., The Humana Press Inc., Totowa, NJ. Chap. 4, p. 67-92, 2005b.45. Vourc’h P, Lacar B, Mignon L, Lucas PA, Young HE, Chesselet MF. Effect of neurturin on multipotent cells isolated from the adult skeletal muscle. Biochem Biophys Res Commun 332:215-223, 2005.46. Henson NL, Heaton ML, Holland BH, Hawkins KC, Rawlings B, Eanes E, Bozof R, Powell S, Grau R, Fortney J, Peebles B, Kumar D, Yoon JI, Godby K, Collins JA, Sood R, Bowyer 3rd FP, Black Jr AC, Young HE. Karyotypic analysis of adult pluripotent stem cells. Histology and Histopathology, 20: 769-784, 2005.​47. Mignon L, Vourc'h P, Romero-Ramos M, Osztermann P, Young HE, Lucas PA, Chesselet MF. Transplantation of multipotent cells extracted from adult skeletal muscles into the adult subventricular zone of adult rats. J Comp Neurol 491:96-108, 2005.48. Young HE, Duplaa C, Katz R, Thompson T, Hawkins KC, Boev AN, Henson NL, Heaton M, Sood R, Ashley D, Stout C, Morgan JH, Uchakin PN, Rimando M, Long GF, Thomas C, Yoon JI, Park JE, Hunt DJ, Walsh NM, Davis JC, Lightner JE, Hutchings AM, Murphy ML, Boswell E, McAbee JA, Gray BM, Piskurich J, Blake L, Collins JA, Moreau C, Hixson D, Bowyer FP, Black AC Jr. Adult-derived stem cells and their potential for tissue repair and molecular medicine. J Cell Molec Med 9:753-769, 2005.49. Young HE, Black AC Jr. Adult-derived stem cells. Minerva Biotechnologica Cancer Gene Mechanisms and Gene Therapy Reviews 17:55-63, 2005.50. Stout CL, Ashley DW, Morgan III JH, Long GF; Collins JA, Limnios JI, Lochner F, McCommon G, Hixson D, Black Jr AC, Young HE. Primitive stem cells reside in adult swine skeletal muscle and are mobilized into the peripheral blood following trauma. American Surgeon 73 (11):1106-1110, 2007.51. Stout CL, McKenzie J, Long G, Henson N, Hawkins KC, Ashley DW, Collins J, Hixson D, Black Jr AC, Young HE. Discovery of pluripotent and totipotent stem cells in the heart of the adult rat. Amer Surg 73:S63, 2007.52. ICMS Stem Cell Lab Practices Guidelines, Version 1.0. Authors: Christopher J. Centeno MD, Michelle Cheever, Wayne Marasco MD PhD, John F Wong PhD, Henry E Young PhD, 18 pgs, © 2009, The International Cellular Medicine Society. (Invited)53. Vourc’h P, Mignon L, Lucas PA, Young HE, Chesselet MF. Cells isolated from adult skeletal muscle express markers of differentiated neurons after transplantation into the adult hippocampus. (In press).54. Young HE and Black Jr AC. Naturally occurring adult pluripotent stem cells. In: Stem Cells: From Biology to Therapy, Advances in Molecular Biology and Medicine. 1st Ed, R.A. Meyers, Ed, WILEY-BLACKWELL-VCH Verlag GmbH & Co. KGaA. Chap 3, pp. 63-93,2013.http://onlinelibrary.wiley.com/doi/10.1002/3527600906.mcb.201200017/abstract.55. Young HE, Hyer L, Black AC Jr, Robinson JS Jr. Adult stem cells: from bench-top to bedside. In: Tissue Regeneration: Where Nanostructure Meets Biology, 3DBiotech, North Brunswick, NJ Chap 1, pp 1-60, 2013a.56. Young HE, Hyer L, Black AC Jr, Robinson JS Jr. Treating Parkinson disease with adult stem cells. J Neurological Disorders, 2:1, 2013b.57. McCommon GW, Lochner F, Black Jr AC, Young HE. Primitive adult-derived stem cells are present in the blood of adult equines and can be increased in number with moderate exercise or ingestion of a cyanobacter, Aphanizomenon flos-aquae. Autocoids 2: 103, 2013.58. Young HE, Black AC. Pluripotent Stem Cells, Endogenous versus Reprogrammed, a Review. MOJ Orthop Rheumatol 1(4): 00019, 2014. Pluripotent stem cells, endogenous versus reprogrammed, a review " MOJ ISSN: 2374-6939MOJOR59. Young HE, Limnios JI, Lochner F, McCommon G, Cope LA, Black AC Jr. Pancreatic islet composites secrete insulin in response to a glucose challenge. J Stem Cell Res 1(1) 001: 1-12, 2017.60. Young HE, Henson NL, Black GF, Hawkins KC, Coleman JA, Black AC Jr. Location and characterization of totipotent stem cells and pluripotent stem cells in the skeletal muscle of the adult rat. J Stem Cell Res 1(1) 002: 1-17, 2017.61. Young HE, Speight MO, Black AC Jr. Functional Cells, Maintenance Cells, and Healing Cells. J Stem Cell Res. 1(1): 003: 1-4, 2017.62. Young HE, Lochner F, Lochner D, Lochner D, McCommon G, Black AC Jr. Primitive Stem Cells in Adult Feline, Canine, Ovine, Caprine, Bovine, and Equine Peripheral Blood. J Stem Cell Res. 1(1) 004: 1-6, 2017.63. Young HE, Lochner F, Lochner D, Lochner D, Black GF, Coleman JA, Young VE, McCommon G, Black Jr AC. Primitive stem cells in adult human peripheral blood. J Stem Cell Res. 1(2) 001:1-8, 2017.64. Young HE, Henson NL, Black GF, Hawkins KC, Coleman JA, Black Jr AC. Stage-Specific Embryonic Antigen-4-Positive Cells and Carcinoembryonic Antigen Cell Adhesion Molecule-1-Positive Cells are Located in the Bone Marrow of the Adult Rat. J Stem Cell Res. 1(2) 001: 1-3, 2017.65. Black Jr AC, Williams S, Young HE. From Bench Top to Bedside: Formation of Pulmonary Alveolar Epithelial Cells by Maintenance Cells and Healing Cells. J Stem Cell Res. 2017; 1(2) 002: 1-16.66. Young HE, Black GF, Coleman JA, Hawkins KC, Black Jr AC. Pulmonary diseases and adult healing cells: from bench top to bedside. J Stem Cell Res 2017; 1(2) 003:1-9.67. Young HE, Limnios JI, Lochner F, McCommon G, Black GF, Coleman JA, Hawkins KC, Black Jr AC. Healing cells in the dermis and adipose tissue of the adult pig. J Stem Cell Res 2017; 1(2) 004:1-5.68. Young HE, Black GF, Coleman JA, Hawkins KC, Williams S, Black Jr AC. Healing cells in the kidney of the adult rat. J Stem Cell Res 2017; 1(3) 001:1-4.69. Young HE, Limnios IJ, Lochner F, McCommon G, Black GF, Coleman JA, Hawkins KC, Black Jr AC. Adult healing cells and cardiovascular disease: From bench top to bedside. J Stem Cell Res 2017; 1(3) 002:1-8.All above publications can be downloaded free of charge from https://www.researchgate.net/profile/Henry_Young/publications/?page=170. Pluripotent Mesenchymal Stem Cells and Methods of Use Thereof: a cell having the capability of extended self-renewal and the ability to form multiple mesodermal lineages in vivo and in vitro. United States Patent Number: 5,827,735.71. Pluripotent Embryonic-Like Stem Cells, Compositions, Methods, and Uses Thereof: a cell having the capability of extended self-renewal and the ability to form multiple ectodermal, mesodermal and endodermal lineages in vivo and in vitro. United States Patent Number: 9,404,895.72. Non-Embryonic Totipotent Blastomere-Like Stem Cells and Uses Thereof. United States Patent Number: 9,616,515.73. Method and System for Repairing Damaged Tissue Using Nucleated Plasma Particles (Nuc-P2s) and Mesodermal Stem Cells (MesoSCs). United State Patent Number: 10,213,465.74. Skeletal Muscle Morphogenetic Protein and Use Thereof: a compound that stimulates the restoration of skeletal muscle in vivo and induces the differentiation of stem cells into a myogenic phenotype in vitro. United States Patent Number: 5,328,695.